title: [The third and new face of Chagas disease].
abstract: After the publication of the results of the BENEFIT study concluding that the benznidazole (5 mg/kg/d/60 d) is ineffective to stop the progression of the established Chagas' cardiomyopathy in adults, the author evokes the new experiences and the new challenges of 2016 regarding Chagas disease while speculating on its future and by calling back some elements little known of his history, in particular the fact that it is Chagas who invented about it to some extent the concept of "neglected disease".
authors.affiliation: CENPETROP - Faculté de médecine de Corrientes, Université dul Nordeste, Nordeste, Argentine. jeanfrancoispays@gmail.com.|Société de pathologie exotique, Hôpital Pitié-Salpêtrière - Pavillon Laveran, 47-83 bld de l'Hôpital, 75651, Paris cedex 13, France. jeanfrancoispays@gmail.com.
authors.forename: J-F
authors.initials: JF
authors.lastname: Pays
mesh_terms: D000328:Adult; D002598:Chagas Cardiomyopathy / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D014355:Chagas Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D002908:Chronic Disease; D018450:Disease Progression; D006801:Humans; D058069:Neglected Diseases; D009593:Nitroimidazoles / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D009593:Nitroimidazoles; C009999:benzonidazole
keywords: BENEFIT; Benznidazole; Chagas disease; Chagas’ cardiomiopathy; Neglected disease; TRAENA; Trypanosoma cruzi